Two readings of largely the same trial and cohort evidence. Hooper/WHO: reducing SFA cuts combined cardiovascular events (RR 0.83, Moderate certainty), so reduce SFA to 10%E (World Health Organization, 2023). Astrup et al. 2020: the evidence does not support a population SFA limit — the events signal rests on a comparator-contaminated trial base, any real benefit may be the replacement not SFA-avoidance, and guidance should be food-based. The held evidence is on Saturated Fat Intake and Replacement and Hooper; this page is the joined issue — and it decomposes, most of the apparent contradiction dissolving into agreement.
Both positions in their own terms
- Hooper / WHO (limit SFA). A Cochrane MA of 15 RCTs (56,675 participants, >=24 months): reducing SFA produces «a potentially important reduction in combined cardiovascular events» — RR 0.83 (0.70-0.98), 15 fewer per 1000, Moderate certainty, the one hard outcome clearing the null. Meta-regression finds the benefit runs through serum-cholesterol lowering and «strengthens our belief that there is a true effect». WHO adopts these numbers into its strong recommendation to reduce SFA to 10%E; its further reduction to <10%E is only a conditional, very-low-certainty suggestion — the certainty-vs-strength split this page’s theme turns on, so the strong arm is the 10%E cap, not the sub-10% target (World Health Organization, 2023). (Hooper et al., 2020)
- Astrup et al. (do not limit SFA; go food-based). A JACC narrative State-of-the-Art Review: “the evidence from both cohort studies and randomized trials does not support the assertion that further restriction of dietary saturated fat will reduce clinical events.” “the dietary recommendation to reduce intake of SFAs without considering specific fatty acids and food sources is not aligned with the current evidence base.” No new trial — the case is re-appraisal + observational (PURE, UK Biobank) + mechanistic. (Astrup et al., 2020)
Parameter table — where the two actually meet, and where they only appear to
| Parameter | Hooper / WHO (View A) | Astrup et al. (View B) | Same quantity? |
|---|---|---|---|
| The decision | reduce SFA to 10%E to reduce CVD | no population SFA limit; food-based guidance | YES — same decision |
| Underlying evidence | 15 long RCTs + cohorts | largely the same RCTs + cohorts, re-appraised | YES — shared base |
| All-cause mortality | RR 0.96 (0.90-1.03), null, Moderate | ”no beneficial effects… on total mortality” | YES — AGREE (both null) |
| CVD / coronary mortality | RR 0.94 / 0.97, null | ”no significant effect on coronary outcomes… or total mortality” | YES — AGREE (both null) |
| Combined CV events (RCT) | RR 0.83 (0.70-0.98), 15 fewer/1000, Moderate, 13 RCTs | the classic diet-heart trials are trans-fat-confounded — but the drop-3-trials attack is aimed at the AHA advisory’s 4-trial core, NOT Hooper’s 13-trial pool | JOINED at the trial-base level — whether the confounding infects Hooper’s RR 0.83 is an untested inference |
| What drives any events benefit | reducing SFA (dose-response via cholesterol) | possibly the PUFA replacement, “not necessarily… an adverse effect of SFAs” | NO — attribution UNRESOLVED by the RCTs |
| Stroke | RR 0.92 (0.68-1.25), null (RCT) | protective with higher SFA (cohort) | NO — different design/unit |
| Evidence tier | Cochrane MA of RCTs, GRADE Moderate | narrative review; re-appraisal + observational + mechanism, no new trial | NO — asymmetric |
The last column is the finding, and it is the opposite of what the SFA-reassessment-vs-consensus framing advertises: on mortality and coronary outcomes the two AGREE — both null. The genuine clash is narrow: the combined-events composite (the one estimate that clears the null) and the attribution of any benefit.
This is a surrogate-disconnect in the Surrogate Outcomes sense: reducing SFA reliably lowers LDL (the surrogate the whole case runs through, LDL ApoB and Cumulative Exposure), yet the effect on the patient-important endpoints — total and coronary mortality — is null, and only a soft combined-events composite clears the bar. The same structure recurs for intentional weight loss (Does Weight Loss Reduce Cardiovascular Events: Look AHEAD moved every surrogate and missed the hard CV endpoint) — a single lever moving a marker is not the same as it moving the outcome.
(Astrup et al., 2020; inferred from Hooper et al., 2020; World Health Organization, 2023)
It decomposes — one distinction, one genuine joined issue
Most of the apparent contradiction is agreement or a scope difference (not-joined checks apply).
- Mortality: they agree. Astrup’s headline that reducing SFA has “no beneficial effects… on cardiovascular disease (CVD) and total mortality” is, for mortality, exactly Hooper’s result — RR 0.96, a well-graded (Moderate) null. The SFA framework page already holds reducing SFA does not measurably reduce dying. On this, the reassessment and the Cochrane MA are the same finding.
- Food-matrix claims are a different unit (check (ii)). Astrup’s dairy/cheese/chocolate/ unprocessed-meat evidence is observational food intake; Hooper measured RCT nutrient substitution. These answer different questions and are consistent once matched — filed as a distinction on Is the Food Category Doing Any Work, not part of this tension.
The joined remainder is real, and it is two linked questions on shared ground:
- Is the classic diet-heart RCT base trans-fat-confounded — and does that infect Hooper’s RR 0.83? Astrup’s live empirical claim: the classic diet-heart trials had partially hydrogenated fish oils (rich in trans fats) in their control-arm margarines, so “the European diets are tests of polyunsaturated fats against trans-plus-saturated fats, which means that any effects described cannot be assigned to saturated fats alone”; “Dropping these 3 studies from a meta-analysis leaves the U.S. trial, which did not find a significant difference between groups for its primary CVD outcome.” Scope this precisely (same-quantity check): the drop-3->null move targets the AHA Presidential Advisory’s 4-core-trial selection (Oslo, London/MRC, Helsinki + LA Veterans; Sacks 2017), NOT Hooper’s 13-trial Cochrane pool — the 3 small European trials do not dominate that pool, so whether removing them would flip RR 0.83 is an untested inference, not a demonstrated null. The genuinely joined issue is therefore at the trial-base level — is the classic diet-heart evidence trans-fat-confounded, and does that contamination reach the pooled estimates guidance relies on? — an appraisal question the two answer oppositely -> Certainty of Evidence vs Strength of Recommendation. (Astrup et al., 2020)
- If RR 0.83 is real, is it SFA harm or PUFA benefit? Astrup: even granting the reduction, it
“could be attributed to a possible beneficial effect of polyunsaturated fatty acids and not
necessarily to an adverse effect of SFAs.” Hooper cannot refute this — its own replacement
subgrouping is underpowered («did not suggest significant differences between replacement of
saturated fat calories with polyunsaturated fat or carbohydrate», with MUFA/protein data «very
limited»), so the RCT evidence lacks the power to separate a PUFA benefit from an SFA harm. The
attribution is genuinely underdetermined by the trials. (A subgroup null taken at face value would,
if anything, point toward SFA-removal doing the work; it is the imprecision, not the null, that
keeps the attribution open.)
(Astrup et al., 2020)
- A second Hooper Cochrane review leans the attribution away from PUFA-addition (2026-08-04).
The omega-6 RCT review — same team, distinct trials — finds that increasing omega-6 does not
reduce CVD events (RR 0.97 [0.81-1.15], Low) or mortality (RR 1.00, Low); only MI (RR 0.88, Low)
and total cholesterol (High) move. The authors state the contrast themselves: «Hooper 2015 and
Sacks 2017 suggest that reducing saturated fat and replacement by polyunsaturated fats reduces the
risk of CVD events, while the present review suggests that increasing omega-6 fats may reduce the
risk of myocardial infarction, but we did not find evidence of an effect on CVD events.» So the
demonstrable RCT lever is the SFA-reduction-with-PUFA package, not PUFA addition per se —
mild evidence that removing/replacing SFA, not adding omega-6, carries the events signal. It does
not close the attribution (both Low certainty, distinct trial sets), but it narrows it. Same
team/method -> F, not
[E-independent]; full weave on Saturated Fat Intake and Replacement. (Hooper et al., 2018)
- A second Hooper Cochrane review leans the attribution away from PUFA-addition (2026-08-04).
The omega-6 RCT review — same team, distinct trials — finds that increasing omega-6 does not
reduce CVD events (RR 0.97 [0.81-1.15], Low) or mortality (RR 1.00, Low); only MI (RR 0.88, Low)
and total cholesterol (High) move. The authors state the contrast themselves: «Hooper 2015 and
Sacks 2017 suggest that reducing saturated fat and replacement by polyunsaturated fats reduces the
risk of CVD events, while the present review suggests that increasing omega-6 fats may reduce the
risk of myocardial infarction, but we did not find evidence of an effect on CVD events.» So the
demonstrable RCT lever is the SFA-reduction-with-PUFA package, not PUFA addition per se —
mild evidence that removing/replacing SFA, not adding omega-6, carries the events signal. It does
not close the attribution (both Low certainty, distinct trial sets), but it narrows it. Same
team/method -> F, not
Hamley 2017 grounds joined-issue 1 — the trial-adequacy reanalysis [2026-08-04]
Joined-issue 1 was filed with the benefit’s trial-base confounding held as an untested inference (Astrup scoped the drop-3 move at the AHA advisory’s 4-core selection, not at a pooled MA). Hamley 2017 is the source that runs the reanalysis — so the inference is now demonstrated, on the replacement-specific pool, and contestable rather than merely asserted. It is an F-refinement of this tension, not a new one (the joined issue already exists here).
What Hamley did. He took the 11 SFA->mostly-n-6-PUFA-replacement diet-heart trials and split them by whether the arms differed in something other than the SFA/PUFA swap — trans fats in control-arm margarines, multifactorial advice (ODHS, STARS), a vitamin-E-deficient control arm (LAVAT), more cardiotoxic thioridazine in the FMHS control arm — calling the confounder-free set adequately controlled (RCOT, MRCT, SDHS, MCS, DART) and the rest inadequately controlled. (Hamley, 2017)
The result is the joined-issue-1 mechanism made visible: the one significant benefit (all-trials total CHD events RR 0.80, 0.65-0.98) vanishes in the adequately-controlled subset (RR 1.02, 0.84-1.23), the confounded subset alone carries it (RR 0.60), and the subgroup difference is significant (P=0.002). Even dropping only the inadequately-randomised FMHS loses significance (0.83, P=0.10). Hamley: «The suggestion of benefits reported in earlier meta-analyses is due to the inclusion of inadequately controlled trials.» (Hamley, 2017)
Parameter table — does this reach the RR 0.83 this page rests on? (same-quantity discipline).
| Parameter | Hamley 2017 | Hooper 2020 / WHO Annex 6 (the RR 0.83 here) | Same quantity? |
|---|---|---|---|
| Intervention | replace SFA with mostly n-6 PUFA (11 diet-heart trials) | reduce SFA, any replacement (15 trials, broader) | NO — replacement-specific vs any-SFA-reduction |
| Outcome | CHD events (total incl. angina; major = MI+sudden death) | CVD events (composite) | NO — CHD-incl-soft vs CVD composite |
| All-trials estimate | total CHD 0.80 (0.65-0.98); major CHD 0.87 (ns) | CVD events 0.83 (0.70-0.98) | near — both ~0.80-0.83, both include the confounded trials |
| Adequacy-filtered estimate | total CHD 1.02 (0.84-1.23), null | no matching cell — Hooper never ran Hamley’s adequacy split | NO — Hooper has no such subgroup |
So the honest reading, even-handed. Hamley demonstrates the confounding-sensitivity on the pool
closest to the replacement question, and his all-trials 0.80 sits right beside Hooper’s 0.83 — material
grounding for joined-issue 1’s mechanism (though a single-author moderate reanalysis, adequate-subset
n=5, is grounding not proof). But Hooper’s broader SFA-reduction pool (RR 0.83) has
not been re-run through the adequacy filter, so «Hamley flips the RR 0.83» remains an inference, now
better-supported but still not a like-for-like recomputation. The joined issue upgrades from untested
to demonstrated-on-the-replacement-pool, unadjudicated on Hooper’s.
(inferred from Hamley, 2017; Hooper et al., 2020; World Health Organization, 2023)
Symmetric standards — Hamley gets the same bar as the pro-consensus pole, and it cuts both ways.
- Against Hamley: the adequacy categorisation was not pre-specified — Hamley concedes «the categorisation is difficult to be based on criteria developed prior to the litera-ture review» and registered no protocol, so his exclusion move carries the post-hoc-selection-bias risk that mirrors the inclusion bias he charges (excluding trials can manufacture a null as readily as including them manufactures a benefit). The adequate subset is 5 trials (4 without SDHS) — the wide CI (1.02, 0.84-1.23) is consistent with a real modest benefit and the null; his own verdict is «unlikely to reduce», not «shown no effect». He further concedes the adequate trials may themselves carry residual TFA confounding, so «the actual RR … may be higher [more beneficial] than what is reported». (Hamley, 2017)
- For Hamley (the halo-check the other way): single-author
moderate, but no funding and no declared competing interests — a cleaner COI than the pro-LA biomarker pole (Marklund’s Unilever support), so it must not be discounted merely for being contrarian. And the confounders he names are real and specific (measured TFA in STARS; documented thioridazine in FMHS), not hand-waving.
A convergence worth naming (not independence). Hamley’s adequately-controlled hard-CHD null
(major CHD 1.06, total CHD 1.02) points the same way as Hooper’s own 2018 omega-6 Cochrane review,
where increasing omega-6 gave CVD events RR 0.97 (Low) — both say that isolating the n-6 PUFA
intervention removes the hard-events signal. That is shared-evidence-base convergence (overlapping
diet-heart trials, both RCT-MAs), NOT an [E-independent] route. The residual clash is narrow and
is exactly this tension’s joined issue: the SFA->PUFA-replacement events benefit the mainstream reviews
report — the SFA Cochrane review’s replacement subgroup RR 0.73 (0.58-0.92, reported inside
Hooper 2018’s discussion; NOT Hooper 2018’s own omega-6-increase estimate, which is 0.97), and
AHA-Sacks 0.71 — vs Hamley’s adequate-only 1.02. Note this figure is itself trial-selection-
sensitive within the mainstream: Hooper 2020’s own update found the replacement subgroups
underpowered / not significantly different (quoted under joined-issue 2 above), so even the pro-benefit
side does not hold 0.73 firmly. The disagreement turns on which trials are adequately controlled, not
on the direction of the underlying data -> Linoleic Acid and Cardiovascular Disease.
(inferred from Hamley, 2017; Hooper et al., 2018, 2020)
Ramsden MCE 2016 grounds the recovered-data arm of joined-issue 1 [2026-08-04]
Joined-issue 1 asks whether the classic diet-heart RCT base is trans-fat-confounded and whether that reaches the pooled estimates guidance relies on. Hamley operationalised the adequacy filter; Ramsden supplies the recovered-data arm — and it converges with Hamley by a second route. This is an F-refinement of the existing joined issue, not a new tension.
What Ramsden did. Recovered the double-blind MCE RCT (1968-73; corn-oil LA 13.2%E replacing SFA) and ran a PRISMA meta-analysis restricted to the SFA->LA-replacement RCTs not confounded by concomitant interventions (MCE, SDHS, RCOT, LA-Vet, MRC-Soy; n=10 808). The result is a mortality null: «no evidence of benefit on mortality from coronary heart disease (1.13, 0.83 to 1.54) or all cause mortality (1.07, 0.90 to 1.27).» (Ramsden et al., 2016)
Parameter table — what Ramsden’s MA does and does not reach (same-quantity discipline).
| Parameter | Ramsden 2016 MA | Hooper 2020 / WHO — the RR 0.83 this page rests on | Same quantity? |
|---|---|---|---|
| Trial pool | 5 SFA->LA-replacement RCTs, confounder-filtered | 15 SFA-reduction, any-replacement RCTs, unfiltered | NO — replacement-specific + filtered vs broad |
| Outcome | CHD mortality 1.13 (0.83-1.54); all-cause 1.07 (0.90-1.27) | combined CV events 0.83 (0.70-0.98) | NO — mortality vs combined-events composite |
| On mortality | null | Hooper’s own mortality rows are also null (all-cause 0.96, CVD-mortality 0.94) | YES — both null, agreement |
So Ramsden’s mortality nulls do not reach or overturn the combined-events RR 0.83 (different outcome);
they reinforce the mortality AGREEMENT already banked at the top of this page. What Ramsden adds to
joined-issue 1 is the second confounder-filter route: like Hamley (adequacy split -> benefit
vanishes), Ramsden’s unconfounded-only pool shows no mortality benefit. Both are shared-evidence-base
RCT-MAs over overlapping diet-heart trials -> F/convergence, NOT [E-independent].
Ramsden’s trans-fat REBUTTAL complicates joined-issue 1 in a decision-relevant way. Astrup’s live claim was that the classic trials tested PUFA against trans+SFA control margarines, so a benefit «cannot be assigned to saturated fats alone». Ramsden argues that for MCE specifically the trans fat was in the control and baseline diets, «(but not the intervention diet). Thus, confounding by dietary trans fat is an exceedingly unlikely explanation for the lack of benefit of the intervention diet.» (Ramsden et al., 2016) The direction matters: trans-fat in the control arm makes the control worse, which biases toward a spurious intervention benefit — so it can inflate a benefit, it cannot manufacture a null. That cuts against using the trans-fat confound to rescue the pro-benefit reading, and it is a genuine intra-field friction between two recovered-data reanalysts (Ramsden) and the reassessment camp (Astrup) over which direction the era’s trans fats bias the estimate. Recorded here, not scored (adjudication is out of ingest scope; the handle sits on joined-issue 1).
Symmetric standards. Ramsden is a high-tier double-blind RCT with a cleaner declared COI (NIH-funded, no financial conflicts) than either pole here — so it is not discounted for being contrarian. But it is one old trial in an institutionalized high-LA-dose population, its full randomized dataset was never recovered (no clean RCT-contrast on mortality), and its 5-trial MA shares the same small, dated, heterogeneous pool whose limits Hamley’s critics also raise. Its contribution is the mortality null on the confounder-filtered replacement pool, converging with Hamley — material grounding for joined-issue 1’s recovered-data arm, not a like-for-like recomputation of Hooper’s RR 0.83. (Hamley, 2017; Hooper et al., 2020; inferred from Ramsden et al., 2016)
The Sydney companion (Ramsden 2013) adds the SECONDARY-prevention recovered arm — and it points the same way on THIS page’s question. SDHS is the second recovered Ramsden trial (single-blind RCT, 458 post-MI men, safflower-oil n-6-selective LA replacing SFA). Its headline is a randomized adverse mortality signal in the LA arm (all-cause HR 1.62, CVD 1.70, CHD 1.74, all borderline) — but for the SFA question specifically the mediation analysis found «the reduction in SFA was not significantly related to any mortality outcome» (the LA rise, not the SFA fall, tracked death). (Ramsden et al., 2013) So SDHS is a replacement-trial result on the LA side, not evidence that cutting SFA helped or harmed. On scope it matches MCE: a mortality signal (not the combined-events RR 0.83), and it pools to non-significance in Ramsden’s own updated MA (LA-selective CHD mortality 1.33, 0.99-1.79, P=0.06). Its trans-fat direction is consistent with the MCE rebuttal — the intervention removed common margarines/shortenings, so «Restriction … in the intervention group would be expected to substantially reduce consumption of trans fatty acids compared with the control group» (Ramsden et al., 2013) — again biasing against a spurious benefit, not manufacturing the adverse signal. Net for joined-issue 1: SDHS reinforces MCE’s recovered-data arm (no benefit from replacing SFA with n-6-selective LA on hard mortality) and adds a secondary-prevention/high-dose stratum where the isolated n-6 sign is adverse — but it is one small single-blind trial, still does not reach RR 0.83, and is already inside Hooper’s pool. Full appraisal on Linoleic Acid and Cardiovascular Disease (The Sydney secondary-prevention arm). NOT independent-E of MCE — same Ramsden recovered-RCT program (Sydney’s MA contains the Minnesota Survey). (inferred from Ramsden et al., 2013, 2016)
Hooper’s OWN risk-of-bias sensitivity analyses partly answer joined-issue 1 — from inside the review [2026-08-17]
Joined-issue 1 (is the events benefit robust to the internal-validity concerns?) was filed here with the adjudication held as an external AWAITS — an independent institutional re-appraisal running an adequacy/confounding filter over Hooper’s own pool. But Hooper already ran a within-review risk-of-bias sensitivity analysis, and it delivers part of that adjudication directly. This is an F-refinement of joined-issue 1, not a new tension.
- Combined events (RR 0.83). The headline survives most sensitivity checks — «This protective effect was confirmed in sensitivity analyses including only trials that aimed to reduce saturated fat…, that significantly reduced saturated fat intake…, that achieved a reduction in total or LDL cholesterol…, or excluding the largest trial (WHI 2006…)» — with the low-risk-of-bias restriction the exception: (Hooper pools WHI as an SFA-reducing arm; on its own primary design WHI was a total-fat->carbohydrate trial that fell far short of its target — the standalone null is on Low-Fat Dietary Pattern and Cardiovascular Disease.) «Analysing including only trials at low summary risk of bias, or using Mantel-Haenszel or Peto fixed-effect analysis suggested more marginal protection (Analysis 1.36…).» The exact figure for the low-RoB combined-events subset is not narratively reported (Analysis 1.36) — only its direction (weaker). (Hooper et al., 2020)
- Myocardial infarction (RR 0.90). Here the low-RoB restriction is quantified and crosses the null: «Sensitivity analyses including only trials at low summary risk of bias (RR 0.93, 95% CI 0.81 to 1.08, Analysis 2.2)… suggested little or no effect, though risk ratios were still all < 1.0.» (Hooper et al., 2020)
The decision-relevant reading. The events benefit is robust to most within-review sensitivity checks but not to the risk-of-bias one — restricting to low-RoB trials weakens the combined-events signal («more marginal protection») and moves MI to a frank null. This is exactly what GRADE’s one-step downgrade to Moderate already encodes (the estimate is not High-certainty precisely because of such limits), so it does not overturn RR 0.83 — the primary estimate stands and the consistency across the other sensitivity analyses is real. What it does is narrow joined-issue 1’s external AWAITS: part of the internal-validity question is answered from inside the review — the events benefit is real but its magnitude is trial-quality-sensitive, and disappears for MI specifically once the low-quality trials are removed. Caveat (why it narrows rather than closes): Cochrane’s «low summary risk of bias» filter is the standard RoB assessment (randomisation, allocation concealment, blinding), not Hamley’s confounding-adequacy filter targeting the trans-fat-comparator specifically — the two overlap but are not identical, so the AWAITS for a confounding-specific re-appraisal of the RR-0.83 combined-events pool still stands.
Correction to a common conflation (the anti-authority catch). The RR 0.93 (0.81-1.08) low-RoB figure is Hooper’s myocardial-infarction sensitivity (Analysis 2.2), not the combined-events one (Analysis 1.36, «more marginal protection», figure unquoted). A critique that pins RR 0.93 (0.81-1.08) on the combined cardiovascular events estimate has swapped the two outcomes — the direction of the claim survives, the label does not. (inferred from Hooper et al., 2020)
The hidden insight
The clash is packaged as is saturated fat bad for the heart? and that is not the load-bearing disagreement. Both sides agree reducing SFA does not reduce mortality; both agree the one positive RCT signal is a combined-events composite; both agree the food matrix is under-studied. The live disagreement is over what a single estimate licenses:
- Hooper/WHO read RR 0.83 as an SFA effect and convert it into an avoid-SFA target.
- Astrup reads the same estimate as (a) possibly confounded and (b) attributable to the replacement, and converts it into a choose-the-replacement-food recommendation.
The decision-relevant payoff: the two converge on the ACTION far more than on the FRAME. The RCT evidence supports replace SFA with PUFA / whole-food unsaturated sources — which is what WHO already recommends (WHO couples the 10%E cap with replacing SFA by PUFA; the LDL-lowering — and WHO’s own certainty — is largest for the PUFA replacement). It does not cleanly support SFA-rich whole foods are harmful — the food-matrix and attribution gaps leave that open. So a person is served the same first move by both camps (shift SFA toward unsaturated fats and whole foods); where they diverge — whether to fear cheese, whole-fat yogurt, dark chocolate and unprocessed meat as SFA sources — is precisely where the evidence is a distinction, not a settled harm. The tension is a worked case of the telos rule: name the substitution, because the substitution sets the sign (Saturated Fat Intake and Replacement), and magnitude ordering is not causal privilege.
Which does the wiki’s method favour? Neither headline — the decomposition. Bank the mortality agreement (a well-graded null, both sides). Hold the combined-events RR 0.83 as Moderate-certainty but with a live, unadjudicated internal-validity challenge (the trans-fat-comparator critique) and a genuinely open attribution (SFA-harm vs PUFA-benefit). Route the food-level questions to the food-matrix diagnostic. Keep the recommendation as a substitution, and let the layer-3 weighting be the person’s.
Evidential asymmetry — symmetric standards, asymmetric conclusion
The two views are not evidentially symmetric, and saying so is the standard working, not bias:
- View A rests on a Cochrane systematic review of 15 RCTs, GRADE Moderate, with a pre-specified protocol and a dose-response meta-regression.
- View B is a narrative review (selection not systematic), introduces no new trial, and its strongest empirical move — post-hoc exclusion of trials on a trans-fat-contamination ground — is principled, but post-hoc exclusion carries the same selection-bias risk it names in others, and inherits that burden (and, per the fix above, it was leveled at the AHA advisory’s small trial set, not shown to overturn Hooper’s pool). Its cohort pillars carry their own confounding (PURE’s high-carb populations are poverty markers; reverse causation in LMIC settings), and its large-vs-small-LDL argument is substantially superseded by apoB particle number (LDL ApoB and Cumulative Exposure — which holds LDL/apoB causal, a point Astrup concedes).
View B’s observational pillar, now grounded — PURE 2017 [2026-07-29]
The cohort evidence View B leans on is Dehghan (135 335
adults, 18 countries) — now held, so the pillar can be read as data rather than a citation. It is the
observational arm of this same joined issue, not an independent route (Astrup already cited it): F,
not [E-independent]. What it grounds, and its limit:
- It reinforces the mortality AGREEMENT, not the events clash. PURE finds higher SFA intake inversely associated with total mortality (HR 0.86 [0.76-0.99]) and stroke (HR 0.79 [0.64-0.98]), and null on major CVD / MI / CVD mortality. On mortality this is the same direction as Hooper’s null — both camps’ evidence says reducing SFA does not reduce dying. (Dehghan et al., 2017)
- It does NOT reach the RR-0.83 events estimate. PURE is an unrandomised level-contrast (13% vs 3%E SFA) confounded by income — the authors concede «residual confounding… cannot be completely excluded» because the highest-carb quintiles are the poorest, on refined-carb subsistence diets. So PURE’s null on CV events cannot overturn Hooper’s randomised RR 0.83; it is the mirror of an income gradient -> The U-Shaped Association Artifact. The full parameter table (PURE vs Hooper RCT, «same quantity?» = NO) is on Saturated Fat Intake and Replacement.
- It independently ranks the PUFA replacement first (carb→PUFA lowers mortality HR 0.89; carb→SFA null on mortality) — consistent with the substitution sets the sign, the tension’s own payoff.
- Provenance flag (record, do not adjudicate): the review derives from a workshop funded by the Nutrition Coalition (self-described nonpartisan-educational, campaigning to revise US nutrition policy), and several authors disclose dairy/beef/low-carb-industry ties. Per the telos this is a process note, not a refutation — but the halo runs the way the funding points, so a favourable-to-whole-fat-dairy conclusion is a tell to scrutinize.
So View B does not overturn RR 0.83; it lodges a legitimate, unadjudicated challenge to its internal validity and a genuinely open attribution question. That is D-fuel — a contested claim with a mechanism — not a symmetric stalemate.
What would move this
- Joined-issue 1 is now partly grounded (Hamley 2017), but the institutional-grade adjudication still
AWAITS. Hamley demonstrates the confounding-sensitivity on the replacement-specific pool, but it is a
single-author
moderate-tier reanalysis with a post-hoc adequacy filter — it does not meet the class-5 bar (a source appraised as rigorously as the guidance, bearing on Hooper’s own pooled estimate). The Ramsden MCE reanalysis is now held (see Ramsden MCE 2016 grounds the recovered-data arm above) — a second confounder-filter route converging with Hamley on the mortality null, but it too reaches only the mortality estimate (Hooper already-null there), not the combined-events RR 0.83. So the AWAITS narrows: what still stands is an independent institutional re-appraisal running an adequacy/confounding filter over Hooper’s broader SFA-reduction combined-events pool (RR 0.83) — that would adjudicate joined-issue 1 properly. The Sydney Diet-Heart companion (secondary prevention) is now ingested (The Sydney companion adds the SECONDARY-prevention recovered arm above): it reinforces the recovered-data mortality arm but, like MCE, does not reach RR 0.83 and is not an independent route — so the institutional-re-appraisal AWAITS still stands. - AWAITS a trial or MR design that separates a PUFA benefit from an SFA harm at matched replacement — that would adjudicate joined-issue 2. Until then the attribution stays open, and replace SFA with PUFA/whole foods is the move robust across both causal models.
Self-critique [run 2026-07-29, before commit]
- Not-joined checks run, and they split the page. The draft risk was filing the whole “SFA
reassessment vs consensus” opposition as one clash. Check (i)/(ii): the mortality rows are AGREEMENT
(both null), not a tension; the food-matrix rows are a different unit (distinction, routed to
Is the Food Category Doing Any Work). The tension is re-altituded to the combined-events estimate
- the attribution, which genuinely are joined (same estimate, contested validity; an attribution the RCTs cannot resolve).
- Counter-passage check RUN on both sides. Hooper’s own subgroup null (PUFA vs carb indistinguishable) is what makes joined-issue 2 real rather than a straw claim; Astrup’s concession that «LDL particles play a causal role» is represented so his LDL argument is not overstated into LDL-denial.
- Parameter table filled with quoted/quantified cells and a defensible “same quantity?” per row — the mortality rows marked AGREE, the events row marked JOINED-but-contested, the attribution and food/stroke rows marked NO with the reason.
- Symmetric standards, asymmetric conclusion made explicit — View B is graded lower on design and its re-appraisal move flagged as the mirror of the fault it names; the COI is recorded as a process flag, not weaponised. Equally, View A is not given a free pass: only one outcome clears the null and mortality is a graded null (both already held on the framework page).
- Not laundered as independence: this is a D (clashing backing over a shared evidence base),
never an E;
confidence: medium— the joined core is real but one side is a single narrative review. - HIGH withheld: stripping the dramatic SFA-stigma framing leaves a narrow, live methodological challenge over one composite estimate — real, but not a HIGH-confidence overturning.
- Blind-subagent pass caught a same-quantity overclaim (fixed before commit). The draft asserted Astrup’s drop-3-trials -> null attack hit Hooper’s RR 0.83 directly (“same estimate”). It does not: in the source, that move is scoped to the AHA Presidential Advisory’s 4-core-trial selection, not Hooper’s 13-trial pool. The parameter-table cell and joined-issue 1 were rescoped to the trial-base level (is the classic diet-heart evidence trans-fat-confounded, and does it reach the pooled estimates?) with the Hooper-pool flip marked an untested inference — the exact failure the parameter-table rule exists to catch. Joined-issue 2 gained the underpowered qualifier (a subgroup null alone points toward SFA-removal; imprecision is what keeps attribution open).
Self-critique [Hamley weave, run 2026-08-04, before commit]
- F-refinement, no new tension. Hamley operationalises the existing joined-issue 1; folded in as grounding rather than minting a duplicate tension. The blind self-critique confirmed this is the right call (the SFA->PUFA-replacement ~0.71-0.73 vs Hamley adequate-only 1.02 is a genuine joined issue on trial-adequacy, not a fake tension).
- Same-quantity discipline held. The parameter table marks Hamley’s replacement-specific CHD-events pool as NOT Hooper 2020’s broader SFA-reduction CVD-events pool (RR 0.83); the prose does not slip into «Hamley refutes 0.83» — it upgrades joined-issue 1 only from untested inference to demonstrated-on-the-replacement-pool, unadjudicated on Hooper’s.
- Convergence marked NOT-E. Hamley’s adequate-only null (1.02) converging with Hooper 2018’s omega-6
null (0.97) is shared-evidence-base (overlapping RCTs),
[E-independent]withheld. - Blind self-critique caught a real attribution defect (fixed before commit). The residual-clash RR 0.73 was first labelled «Hooper 2018’s PUFA-replacing-SFA subgroup». It is the SFA Cochrane review’s replacement subgroup, quoted inside Hooper 2018’s discussion — Hooper 2018’s own omega-6-increase estimate is 0.97, so one label was carrying two different reviews’ numbers. Relabelled to the SFA-review lineage and reconciled with Hooper 2020’s underpowered-subgroup finding. Same fix applied on Linoleic Acid and Cardiovascular Disease.
- Symmetric standards, evenhanded. Hamley’s post-hoc adequacy filter (author-conceded), 5-trial subset and null!=no-effect are flagged; its cleaner declared COI (no funding, none declared) is noted without privileging. «strong grounding» softened to «material grounding».
Self-critique [Ramsden MCE weave, run 2026-08-04, before commit]
- F-refinement, no new tension. Ramsden grounds the existing joined-issue 1 (recovered-data arm), converging with Hamley by a second confounder-filter route; folded in, not minted as a duplicate clash.
- Same-quantity discipline held. The parameter table marks Ramsden’s MA as mortality (CHD/ all-cause), NOT the combined-events RR 0.83; the prose does not slip into «Ramsden refutes 0.83» — it reinforces the mortality agreement already banked, and leaves the events estimate untouched.
- Convergence marked NOT-E. Ramsden and Hamley are shared-evidence-base RCT-MAs (overlapping
diet-heart trials; MCE sits inside both Hooper’s and Hamley’s pools), so
[E-independent]withheld. - Counter-passage / the trans-fat direction read carefully. Ramsden’s trans-fat rebuttal (trans fat in control, not intervention -> biases toward benefit, cannot make a null) is represented as a genuine friction against Astrup’s use of the confound, and explicitly recorded not scored (adjudication is out of ingest scope).
- Symmetric standards. Ramsden’s cleaner COI is noted without privileging the contrarian pole; its one-old-trial / never-recovered-full-dataset / high-dose-institutionalized limits are stated.